Boess Gruppe
| Primary URL | Location | Industry | Undetermined |
Country
Germany
|
Manufacturing
|
|---|
Profile
Boess Gruppe is an electrical engineering firm with its headquarters located in Germany. The company operates from thirteen distinct locations, indicating a multi‑site operational presence. As an electrical engineering provider, its core activities involve the planning, implementation, and maintenance of electrical systems for various clients. The firm serves markets that require reliable electrical infrastructure, which may include industrial, commercial, and public‑sector projects. Its thirteen‑site footprint suggests a capacity to undertake projects across a regional or national scale. The organisation’s focus on electrical engineering distinguishes it from broader consultancies that offer a wider range of disciplines. No public information about the company’s ownership structure or parent‑subsidiary relationships is available in the supplied sources.
In May 2023, Boess Gruppe was affected by a ransomware attack that targeted its IT service provider, Unico Data. The Play ransomware group encrypted Unico Data’s systems during a holiday weekend, leading to widespread service disruptions for numerous clients. As a result, Boess Gruppe experienced interrupted online services and administrative functions, although its core engineering operations were not reported to have suffered safety‑critical impacts. The incident also impacted other Unico Data customers, including Pathé cinemas, PB Swiss Tools, the Rüegsau municipality, and the Siloah Group, which relied on manual processes while restoring IT. Unico Data collaborated with law‑enforcement authorities to gradually restore services, though the attackers taunted victims on darknet leak sites and recovery timelines remained unclear. The event highlighted the dependence of modern engineering firms on external IT providers and underscored the importance of robust cyber‑risk management in the sector. While the disruption caused operational challenges, there were no indications that patient safety or product quality was compromised at any of the affected entities.